false
0001868279
0001868279
2025-06-18
2025-06-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 18, 2025
ARRIVENT BIOPHARMA, INC.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-41929 |
|
86-3336099 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
18 Campus Boulevard, Suite 100
Newtown Square, PA |
|
19073 |
| (Address
of principal executive offices) |
|
(zip
code) |
Registrant’s telephone number, including
area code: (628) 277-4836
N/A
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Stock,
$0.0001 par value per share |
|
AVBP |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote
of Security Holders.
On June 18, 2025, ArriVent
BioPharma, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) via live audio
webcast on the Internet. Of the 34,045,193 shares of common stock, par value $0.0001 per share, issued and outstanding and eligible to
vote as of the record date of April 21, 2025, a quorum of 25,159,248 shares, or 73.89% of the eligible shares, was present at the meeting
or represented by proxy.
At the Annual Meeting,
the stockholders: (1) elected each of Zhengbin (Bing) Yao, Ph.D. and Kristine Peterson to the Company’s board of directors
as a Class I director for a term of three years to serve until the 2028 annual meeting of stockholders and until his or her successor
is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”); and (2)
ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2025 (“Auditor Ratification”). A more complete description of each of these matters is set forth
in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2025.
The number of votes cast
in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes
on each of the foregoing matters are set forth below.
1. Election of Directors
| Nominee | |
Shares Voted For | |
Shares Voted to Withhold
Authority | |
Broker Non-votes |
| Zhengbin (Bing) Yao, Ph.D. | |
| 22,116,332 | |
| 442,833 | |
| 2,600,083 |
| Kristine Peterson | |
| 21,932,842 | |
| 626,323 | |
| 2,600,083 |
2. Auditor Ratification
| Shares Voted For | |
Shares Voted Against | |
Shares Abstaining | |
Broker Non-votes |
| 24,991,469 | |
| 242 | |
| 167,537 | |
| 0 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
ARRIVENT BIOPHARMA, INC. |
| |
|
|
| |
By: |
/s/ Winston Kung |
| |
|
Winston Kung |
| |
|
Chief Financial Officer and Treasurer |
Date: June 20, 2025
